Therapy of secondary hyperparathyroidism to date: Vitamin D analogs, calcimimetics or both?

Journal of Nephrology

Volumn 19, Issue 4, 2006, Pages 399-402

  Cannella, Giuseppe ^a   Messa, Piergiorgio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Calcimimetics; Calcitriol; Cinacalcet; Paracalcitol; Secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE; ERGOCALCIFEROL; NAPHTHALENE DERIVATIVE;

CALCIUM BLOOD LEVEL; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; DRUG MARKETING; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LIFE EXPECTANCY; METABOLIC ACIDOSIS; METABOLIC BONE DISEASE; NONHUMAN; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; REBOUND; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; UREMIA; VITAMIN D DEFICIENCY;

CALCITRIOL; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; NAPHTHALENES;

EID: 34250650051     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Arnaud CD. Hyperparathyroidism and renal failure. Kidney Int 1973; 4: 89-97.
2. Silver J, Levi R. Cellular and molecular mechanism of secondary Hyperparathyroidism. Clin Nephrol 2005; 63: 119-26.
3. Mak RH. Early history of renal rickets. Am J Nephrol 1993; 13: 293-7.
4. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, De Grandi R, Augeri C, Claudiani F, Di Maio G. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46: 1124-32.
5. Foley RN, Suying L, Jiannong L, Ilbertson DT, Shu-Cheng C, Collins AJ. The fall and the rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16: 210-8.
6. Cannella G, Moriero E, Rolla D. Practical guidelines for effective treatment of osteodystrophic uremic syndrome with intravenous calcitriol. Nephrol Dial Transplant 1996; 11 (Suppl 3): 50-3.
7. Chertow GM, Burke SK, Lazarus JM. Polyallylamine hydrochloryde (Renagel): A non calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
8. Block GA, Hulbert-Sheraton TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-17.
9. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR. Treatment of hyperphospatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE) study. Kidney Int 2004; 65: 1914-26.
10. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-vitamin-D2 and 1,25-vitamin-D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-84.
11. Sprague SM, Llach F, Amdhal M. Paracalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1480-90.
12. Brown EM, Mc Leod J. Extracellular calcium sensing and extracellular calcium signalling. Physiol Rev 2001; 81: 239-97.
13. Cohen A, Silverberg SJ. Calcimimetics: therapeutics potential in hyperparathyroidism. Curr Opin Pharmacol 2002; 2: 734-9.
14. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D. Cinacalcet HC1 attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-76.
15. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani NJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-25.
16. Napgal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-87.
17. Holick MF. Vitamin for health and in chronic kidney disease. Semin Dial 2005; 18: 266-75.
18. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
19. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005; 68: 1973-81.
20. Mc Clellan WM, Chertow GM. Beyond Framingham: cardiovascular risk profiling in ESRD. J Am Soc Nephrol 2005; 16: 1539-41.
21. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25.
22. Nilius B, Weidema F, Prenen J, Hoenderop JG, Vennekens R, Hoefs S, Droogmans G, Bindels RJ. The carboxyl terminus of the epithelial Ca(2+) channel EcaC1 is involved in Ca(2+)-dependent inactivation. Pflugers Arch 2003; 445: 584-8.
23. Tfelt-Hansen J, Brown EM. The calcium-sensihg receptor in normal physiology and pathophysiology: a review. Grit Rev Clin Lab Sci 2005; 42: 35-70.
24. van Abel M, Hoenderop JC, Bindels RJ. The epithelial calcium channels TRPV5 and TRPV6: regulations and implications for diseases. Naunyn Schmiedebergs Arch Pharmacol 2005; 371: 295-306.
25. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Tadani R. Survival of patients undergoing hemodialysis with paracalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.